Onychomycosis in psoriatic patients - Rationalization of systemic treatment

Mycoses

Volumn 53, Issue 4, 2010, Pages 340-343

  Shemer, Avner ^a   Trau, Henri ^a   Davidovici, Batya ^b   Grunwald, Marcelo H ^c   Amichai, Boaz ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b KAPLAN MEDICAL CENTER   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Itraconazole; Onychomycosis; Psoriasis

Indexed keywords

ITRACONAZOLE; ANTIFUNGAL AGENT;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; HYPERKERATOSIS; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; NAIL COLOR DEFECT; NAIL DISEASE; NAIL DYSTROPHY; ONYCHOLYSIS; ONYCHOMYCOSIS; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; TREATMENT RESPONSE; ADOLESCENT; CHILD; COMPLICATION; MICROBIOLOGY; MIDDLE AGED; NAIL; PATHOLOGY; PRESCHOOL CHILD; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; NAILS; ONYCHOMYCOSIS; PREVALENCE; PSORIASIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953354895     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2009.01726.x     Document Type: Article

References (18)

1. Scher RK. Psoriasis of the nail. Dermatol Clinic 1985 3 : 387 394.
2. Gupta AK, Lynde CW, Jain HC et al. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. Br J Dermatol 1997 136 : 786 789.
3. Salomon J, Szepietowski JC, Proniewicz A. Psoriatic nails: a prospective clinical study. J Cutan Med Surg 2003 7 : 317 321.
4. Baran R. Etretinate and the nails (study of 130 cases) possible mechanisms of some side-effects. Clin Exp Dermatol 1986 11 : 148 152.
5. Sánchez-Regaña ML, Videla S, Villoria J et al. Prevalence of fungal involvement in series of patients with nail psoriasis. Clin Exp Dermatol 2008 33 : 194 195.
6. Szepietowski JC, Salomon J. Do fungi play role in psoriatic nails? Mycoses 2007 50 : 437 442.
7. Leibovici V, Hershko K, Ingber A, Westerman M, Leviatan-Strauss N, Hochberg M. Increased prevalence of onychomycosis among psoriatic patients in Israel. Acta Derm Venereol 2008 88 : 31 33.
8. English MP. Nails and fungi. Br J Dermatol 1976 94 : 697 701.
9. Shemer A, Davidovici B, Trau H, Grunwald M, Amichai B. New criteria for the laboratory diagnosis of nondermatophyte moulds in onychomycosis. Br J Dermatol 2009 160 : 37 39.
10. Barrera MV, Habicheyn S, Mendiola MV et al. Etancercept in the treatment and retreatment of psoriasis in daily clinical practice. Eur J Dermatol 2008 18 : 683 687.
11. Rich P, Gtriffiths CE, Reich K et al. Baselone nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008 58 : 224 231.
12. Lamerson C, Stevens G, Sax K. Treatment of nail psoriasis with efalizumab: a preliminary study. Cutis 2008 82 : 217 220.
13. Gupta AK, Gover MD, Lynde CW. Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. J Eur Acad Dermatol Venereol 2006 20 : 1188 1193.
14. Drake LA, Patrick DL, Fleckman P et al. The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life. J Am Acad Dermatol 1999 41 : 189 196.
15. Chen Sc, Sorrell T. Antifungal agents. Med J Aust 2007 187 : 404 409.
16. Pauluzzi P, Boccucci N. Inverse psoriasis induced by terbinafine. Acta Derm Venereol 1999 79 : 389.
17. Szepietowski JC. Terbinafine exacerbates psoriasis: case report with a literature review. Acta Dermatovenerol Croat 2003 11 : 17 21.
18. Kaçar N, Ergin S, Ergin C, Erdogan BS, Kaleli I. The prevalence, aetiological agents and therapy of onychomycosis in patients with psoriasis: a prospective controlled trial. Clin Exp Dermatol 2007 32 : 1 5.